Loading...
SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
The 34-week double-blind placebo-controlled main phase of REAL 1 (NCT02229851) has been previously presented (Johannsson G et al. 2018.). Now we report the open-label extension of this trial evaluating efficacy and safety of somapacitan in male/female patients aged 23-79 years with AGHD, for an addi...
Saved in:
| Published in: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Endocrine Society
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552458/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-LB074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|